Management Team

Klaus Dembowsky, MD, PhD

CEO

Dr. Klaus Dembowsky has more than 25 years experience in research and development for pharmaceutical and biotech companies. After earning his medical degree in Heidelberg he was working in neurophysiological research and habilitated in 1988. He continued his career in the pharmaceutical industry where numerous innovative drugs were brought into clinical development under his leadership, one drug being on the market. After more than 10 years in the cardiovascular research institute at Bayer he served in different management positions in the biotech industry (VP Drug Discovery at Ingenium Pharmaceuticals, Managing Director at Speedel Experimenta, Chief Medical Officer at Polyphor). In May 2015 he was appointed CEO of amcure and strengthens the management team with his broad experience.

Matthias Klaften, PhD

COO&CFO

Dr. Matthias Klaften is one of the co-founders of amcure. Before he was working as business development manager and consultant for Spin-Off projects in the department of innovation management at the Karlsruhe Institute of Technology (KIT). Dr. Klaften studied Biology in Karlsruhe and Munich. He worked for a US biotech company before he passed his PhD at the Institute for Experimental Genetics at the Helmholtz Zentrum München. As a project leader he was in charge of several innovation projects for medical technology funded by the Helmholtz Society, by the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Technology (BMWi). He has expertise in the development of high-tech projects and provided advice for biotech start-up projects and companies. As Chief Operating Officer and Chief Financial Officer he takes over the operative management of amcure.

Alexandra Matzke-Ogi, PhD

Head of Exploratory Research

Dr. Alexandra Matzke is one of the co-founders of amcure. Before she worked as postdoctoral fellow at the Institute of Toxikology (ITG) and Genetics at the KIT . During her work as a PhD candidate she developed the CD44v6 blocking peptides and investigated their inhibitory effect in cancer. These peptides are the basis of the R&D activities of amcure. As project leader she was in charge of several innovation projects dealing with the development of CD44v6 blocking agents towards therapeutic use funded by the Helmholtz Society and the Federal Ministry of Economics and Technology (BMWi). As Head of Exploratory Research she is part of the management team of amcure.

Oliver Coutelle, MBBS, PhD

Head of Translational Research

Dr. Oliver Coutelle has more than 15 years of experience in biomedical research and clinical oncology. He first obtained his BSc in Biochemistry at Imperial College, London before conducting research in the field of developmental biology at the National Institute for Medical Research (NIMR) where he received his PhD from University College London (UCL) in 1997.  He obtained his medical degree from Cambridge University and Imperial College in 2003 and trained in hematology and clinical oncology at the University Hospital Cologne, Germany. In parallel he lead a research team and authored a number of research papers in the field of angiogenesis and biomarkers in oncology. In 2017 he joined amcure as head of translational research to strengthen the research team with his experience in research and oncology.

Klaus Bender, PhD

Head of Clinical Development

Dr. Klaus Bender has more than 20 years experience in pharmaceutical and biotech companies.  After earning his Ph.D. at the Swiss Tropical Institute (Basel, Switzerland), he was working in the research area for three years at The Weizmann Institute of Science (Israel), prior to joining the pharmaceutical industry in 1996.  He had leading positions in pharmaceutical companies and biotechs with focus on Clinical Research and Development, and Medical Marketing. He acted as sponsor of clinical studies for seven years at Acino Pharma AG.  In February 2016, he was appointed Head of Clinical Development at amcure GmbH and strengthens the clinical development team with his broad clinical and R&D experience.